XLV - Health Care Select Sector SPDR ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
88.40
+1.56 (+1.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close86.84
Open86.96
Bid86.64 x 800
Ask87.01 x 2200
Day's Range86.94 - 88.42
52 Week Range78.74 - 96.06
Volume10,535,721
Avg. Volume13,412,085
Net Assets17.98B
NAV86.43
PE Ratio (TTM)N/A
Yield1.58%
YTD Return6.28%
Beta (3Y Monthly)1.01
Expense Ratio (net)0.13%
Inception Date1998-12-16
Trade prices are not sourced from all markets
  • Analysts’ Recommendations for AbbVie in January
    Market Realist2 days ago

    Analysts’ Recommendations for AbbVie in January

    Merck & Co. or AbbVie: Which Is Performing Better This Month? On January 10, AbbVie’s market cap was $132.91 billion. Based on its closing price on January 10, the company had reported returns of 2.21% in the last week, 0.67% in the last month, and -6.74% in the last quarter.

  • Top-Ranked Sector ETFs & Stocks to Buy for 2019
    Zacks6 days ago

    Top-Ranked Sector ETFs & Stocks to Buy for 2019

    Investors could be well served by ETFs and stocks from top-ranked sectors.

  • What Analysts Are Recommending for Teva Pharmaceutical in January
    Market Realist7 days ago

    What Analysts Are Recommending for Teva Pharmaceutical in January

    Teva or Mylan: Which Is the Better Generic Play in January? ## TEVA’s price movements Teva Pharmaceutical (TEVA) is a leading global pharmaceutical company with a market cap of $17.21 billion as of January 8. On the day, the company closed at $17.68 on the NYSE, up 0.06% from its previous closing price. On January 2, Teva Pharmaceutical issued a press release announcing the settlement of an ongoing patent infringement litigation with Amgen (AMGN) related to the latter’s secondary hyperparathyroidism drug, Sensipar. Based on its closing price on January 8, the company had reported returns of 14.66% in the last week, -12.73% in the last month, and -17.77% in the last quarter. Teva Pharmaceutical had also reported returns of -27.09% in the last half year, -8.01% in the last year, and 14.66% YTD (year-to-date). Based on its closing price on January 8, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) had reported returns of 0.52% in the last week, -6.42% in the last month, and -7.77% in the last quarter. XLV had also reported returns of 0.37% in the last half year, 2.01% in the last year, and 0.52% YTD. ## Analysts’ recommendations and target prices for Teva The 12-month consensus analyst recommendation for Teva Pharmaceutical as of January 9 is a “hold.” The 12-month consensus target price for the company is $22.71, 28.45% higher than its closing price on January 8. The highest target price estimate for the company is $30, and the lowest target price estimate is $15. Of the 23 analysts covering Teva Pharmaceutical on January 9, two analysts have rated the company as a “strong buy,” three have rated it as a “buy,” 15 have rated it as a “hold,” and three have rated it as a “sell.” In the next article, we’ll discuss analysts’ recommendations for Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?

  • MarketWatch7 days ago

    Illumina sees Q4 revenue above expectations, provides a mixed outlook

    Illumina Inc. provided Wednesday a fourth-quarter revenue estimate that was above expectations, and provided a mixed outlook for 2019. The stock was still inactive in premarket trade. The genetics analysis company's Chief Executive Francis deSouza said at the J.P. Morgan Healthcare Conference that fourth-quarter revenue rose 11% from a year ago to $865 million, which was above the FactSet consensus of $862 million, while full-year revenue rose 21% to $3.3 billion. For 2019, deSouza said revenue growth is expected to be 13% to 14%, while the current FactSet consensus of $3.81 billion is about 15% above 2018 revenue of $3.3 billion. The company expects 2019 adjusted earnings per share, which excludes non-recurring items, of $6.50 to $6.60, compared with the current FactSet consensus of $6.44. Illumina's stock has lost 9.3% over the past three months, while the SPDR Health Care Select Sector ETF has declined 7.9% and the S&P 500 has shed 10.6%.

  • Three Healthcare Stocks Rallying Over 10% Today
    Market Realist9 days ago

    Three Healthcare Stocks Rallying Over 10% Today

    Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.

  • MarketWatch9 days ago

    Hologic's stock surges after revenue outlook beats expectations

    Shares of Hologic Inc. ran up 4.7% in premarket trade Monday, after the medical technology company provided a fiscal first-quarter revenue outlook that was above expectations. The company said it expects revenue for the quarter ended Dec. 29 of $831 million, up 55 from a year ago, and above the FactSet consensus of $812 million. Among its largest business segments, the company expects breast health revenue to rise to $325 million from $288 million, above the FactSet consensus of $305 million, and expects diagnostics revenue to grow to $297 million from $285 million, better than expectations of $290 million. The company is expected to report full results in early February. The stock has slipped 3.3% over the past three months, while the SPDR Health Care Select Sector ETF has lost 8.8% and the S&P 500 has declined 12.3%.

  • MarketWatch9 days ago

    Lilly to buy Loxo Oncology in a $8 billion deal, for a 68% premium

    Shares of Loxo Onocology Inc. were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co. in a deal valued at $8.0 billion. Lilly's stock fell 2.7% in ahead of the open. Under terms of the deal, Lilly will pay $235 in cash for each Loxo share outstanding, which represents a 68% premium to Friday's closing price of $139.87, and 24% above Loxo's record close of $189.96 on July 6, 2018. The deal is the largest in a series of acquisitions by Lilly to broaden its cancer treatment efforts, Lilly said. The deal is expected to close by the end of the first quarter. The company said it will provide an update to 2019 financial guidance, when it reports fourth-quarter results on Feb. 13. Loxo shares have lost 12.4% over the past three months and Lilly shares have eased 0.3%, while the SPDR Health Care Select Sector ETF has shed 8.8% and the S&P 500 has declined 12.3%.

  • ETF Trends11 days ago

    Some Value Remains With HealthCare ETFs

    Compared to other sectors, healthcare was sturdy in 2018 and while the sector looks close to being fairly valued, the group could offer more upside this year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • ETF Trends12 days ago

    Healthcare ETFs Could Lead Again in 2019

    Healthcare, the second-largest sector weight in the S&P 500, was the best-performing sector in the U.S. last year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year and some analysts believe more upside is in store for the healthcare sector in 2019. Consequently, investors may also turn to defensive sectors that are less economically sensitive, such as health care.

  • GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth
    Market Realist12 days ago

    GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth

    Will Restructuring Initiatives Put GE Back on Growth Trajectory? As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity. The move is believed to be another step by newly appointed CEO Larry Culp to optimize the company’s business and strengthen its liquidity position.

  • US Job Additions and Unemployment: What Do Markets Expect?
    Market Realist13 days ago

    US Job Additions and Unemployment: What Do Markets Expect?

    The non-farm payrolls for the US (IVV) (QQQ) were 155,000 in November, which underwhelmed economists’ consensus of 198,000. October’s non-farm payrolls (or NFP) were also revised down to 237,000 from 250,000 previously, while September’s NFP were revised higher by 1,000 to 119,000. After last month’s weaker job additions, economists are expecting payrolls to come in at 180,000, which is lower than the average for the first 11 months of 2018 but still healthy.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks14 days ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • Stocks slide in first session of 2019
    Yahoo Finance Video14 days ago

    Stocks slide in first session of 2019

    Yahoo Finance's LIVE market coverage and analysis, beginning each day at 11:30 a.m. ET.

  • CNBC14 days ago

    House Democrats move to save Obamacare from death blow

    House Democrats have set up rules for the new Congress that give the Speaker of the House the authority to intervene in a federal court case challenging the constitutionality of Obamacare. A coalition of Democratic state attorneys general, led by California's Xavier Becerra, intends to appeal. Democrats about to take over control of the House of Representatives have moved to defend Obamacare from a court challenge that threatens to kill the landmark health-care reform law.

  • 10 Top-Ranked ETFs That Crushed the Market in 2018
    Zacks14 days ago

    10 Top-Ranked ETFs That Crushed the Market in 2018

    While there have been losers in most corner of the space, several ETFs still managed to end the year in green and are likely to continue outperforming in 2019 too.

  • Hello 2019 — What to know in markets Wednesday
    Yahoo Finance15 days ago

    Hello 2019 — What to know in markets Wednesday

    Markets open for the first full day of trading in 2019 on Wednesday.

  • Dow jumps on trade optimism
    Yahoo Finance16 days ago

    Dow jumps on trade optimism

    Yahoo Finance's LIVE market coverage and analysis, beginning each day at 11:30 a.m. ET.

  • Pfizer’s Prevnar 13 and Other Developments
    Market Realist21 days ago

    Pfizer’s Prevnar 13 and Other Developments

    An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Prevnar 13 revenue Pfizer’s (PFE) Prevnar (or Prevenar) 13 is used to prevent pneumococcal diseases. In the first nine months of this year, Prevnar 13 sales grew ~5% YoY (year-over-year) to $4.

  • How Pfizer’s Oncology Business Is Positioned
    Market Realist23 days ago

    How Pfizer’s Oncology Business Is Positioned

    Pfizer’s (PFE) oncology revenue rose ~16% YoY (year-over-year) to $5.3 billion in the first nine months of this year. Its net oncology revenue grew 8% YoY to $3.4 billion in US markets and 35% YoY to $1.9 billion in international markets.

  • Safe Haven Stocks Are The Market’s New Victim
    Investopedia26 days ago

    Safe Haven Stocks Are The Market’s New Victim

    Wells Fargo equity derivatives strategist Pravit Chintawongvanich says that defensive sectors have been the beneficiaries of large asset inflows but that a broad pullback might suggest the sector rotation may be coming to an end, according to a detailed analysis in Barron’s. This week saw the utilities and real estate sectors join in, off 3.2% and 3.8%, respectively, since last Thursday.

  • MarketWatch28 days ago

    Eli Lilly's stock gains after upbeat profit and revenue outlook, raised dividend

    Shares of Eli Lilly & Co. rallied 1.0% in premarket trade Wednesday, after the drug giant provided 2019 profit and revenue guidance that was above expectations, and raised its dividend by 15%. The company said it expects 2019 net earnings per share of $5.52 to $5.62, and adjusted EPS excluding non-recurring items of $5.90 to $6.00, which is above the FactSet consensus of $5.82. Lilly projects revenue to be $25.3 billion to $25.8 billion, up from its 2018 guidance of $24.3 billion to $24.5 billion, and above the FactSet consensus of $24.74 billion. Lilly said revenue growth is expected to come from volume from newer medicines, including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant and Lartruvo, as well as from the recent launch of Emgality, partially offset by lower revenue from Cialis. Separately, the company said it raised its quarterly dividend to 64.5 cents a share from 56.25 cents. Based on Tuesday's stock closing price of $106.50, the new annual dividend rate implies a dividend yield of 2.42%, compared with the implied yield for the S&P 500 of 2.18%, according to FactSet. Lilly's stock has gained 0.7% over the past three months through Tuesday, while the SPDR Health Care Select Sector ETF has lost 7.7% and the S&P 500 has shed 12.4%.

  • New highs are coming this year, says Canaccord Genuity
    CNBC Videos8 days ago

    New highs are coming this year, says Canaccord Genuity

    Tony Dwyer, Canaccord Genuity, says new highs are coming this year. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Guy Adami.

  • ETF Spotlight: Best & worst performing sector ETFs of 201...
    CNBC Videos21 days ago

    ETF Spotlight: Best & worst performing sector ETFs of 201...

    CNBC's Bob Pisani reports on the best and worst performing sector ETFs this year.